InsidersTradesSigma
NFL Biosciences Stock: price and directors' dealings · France · AMF
Track the NFL Biosciences stock price and the full management transaction log of the company, a listed issuer based in France. Shares are quoted on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, NFL Biosciences has published 9 insider filings. Market capitalisation: €11.5m. The latest transaction was disclosed on 8 September 2025 (Cession). Among the most active insiders: Bruno Lafont. The full history is accessible without an account.
9
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€353,635
5 ops.
Sell Volume
42Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 September 2025
Declarations9 total
18,000 shares@ €1.52255.9% of flowActionEuronext Growth Paris2025DD1056681
41,650 shares@ €1.188210.7% of flowActionEuronext Growth Paris2025DD1049758
250,000 shares@ €0.3016.2% of flowActionEuronext Growth Paris2025DD1032010
6,568 shares@ €2.5814100.0% of flowActionEuronext Growth Paris2023DD920561
500,000 shares@ €0.1010.8% of flowActionEuronext Growth Paris2023DD918253
57,000 shares@ €2.653932.8% of flowActionEuronext Growth Paris2023DD918168
43,000 shares@ €2.523623.5% of flowActionEuronext Growth Paris2023DD918207
71,778 shares0ActionEuronext Growth Paris2023DD897035
71,778 shares0ActionEuronext Growth Paris2023DD896929
9 of 9 declarations
About NFL Biosciences
NFL BIOSCIENCES is a French biopharmaceutical company listed on Euronext Growth Paris under ISIN FR0014003XT0 and ticker ALNFL. Headquartered in Castelnau-le-Lez, near Montpellier, the company develops innovative botanical medicines for the treatment of addictions, with a long-standing focus on smoking cessation. Its model is that of a specialty biotech centered on plant-derived drug candidates, designed to be licensed to pharmaceutical partners rather than widely marketed directly by the company. This partnership-led strategy allows NFL BIOSCIENCES to concentrate on research, clinical validation and intellectual property value creation. The company was co-founded in 2009 by Bruno Lafont, who now serves as Chairman of the Board and CEO, with the ambition of turning botanical extracts into standardized, reproducible therapies that can meet strict regulatory requirements. Its pipeline is built around several programs. NFL-101 is the most advanced candidate; it is a standardized tobacco-leaf extract developed to help smokers quit. NFL-102 is another smoking-cessation candidate aimed at a broader population, while NFL-301 is focused on excessive alcohol consumption and is based on kudzu extract. The company emphasizes a scientific approach rooted in the biology of addiction, aiming to go beyond symptom relief and address the underlying neurobiological mechanisms that drive dependence and relapse. NFL BIOSCIENCES also stands out for its structured intellectual-property portfolio, which includes multiple patent families, and for its lean operating model with outsourced research and controlled fixed costs. Manufacturing is carried out in France in compliance with Good Manufacturing Practices, reinforcing the industrial credibility of the platform. In 2025 and early 2026, the company continued to advance its clinical and regulatory programs while securing additional funding from long-standing supporters such as Bpifrance. Following an April 2026 bond financing, its cash runway was extended to the third quarter of 2027, an important visibility factor for a pre-commercial biotech. Overall, NFL BIOSCIENCES is positioned as a niche French biotechnology company with exposure to the addiction-treatment market and a value-creation strategy centered on licensing.
